/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
$70.63
$1.16 (-1.62%)
Live · 07:17 PM
Margins and capital returns are both well above average: 50.09% operating margin, ROIC at 216.49%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 114.5% YoY with margins expanding 87.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.01B
▲ +114.5% YoY
Net Income (TTM)
-$38M
▲ +287.9% YoY
Op. Margin
12.45%
▲ +87.6pp YoY
ROIC
20.89%
▲ +275.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$40M
▲ +715.1% YoY
Op. Cash Flow (TTM)
-$31M
▲ +760.4% YoY
Net Debt
-$1.53B
Net Cash Position
Cash & Equiv.
$2.23B
5Y CAGR: +35.4%
Continue Research
SourceComputed from the 10-Q filed 30 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
PTC Therapeutics (PTCT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, PTC Therapeutics scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
PTC Therapeutics scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 12.5% operating margin and a 20.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PTCT's valuation and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.